GSK slides 6% after US CDC narrows scope of RSV shots

- GSK's shares dropped more than 6% on Thursday, a day after a U.S. public health agency narrowed its usage recommendation for all respiratory syncytial virus vaccines and held off on recommending their use for those under 60 years of age.

The U.S. Centers for Disease Control and Prevention said late on Wednesday that it now recommended the shots for those who are 60-74 years old and have an increased risk of severe RSV due to medical conditions. The decision is a negative for GSK, which makes the Arexvy RSV vaccine, analysts at JPMorgan wrote in a note.Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events.

Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.would like to remind you that the data contained in this website is not necessarily real-time nor accurate.

It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

United States Latest News, United States Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

FDA approves first RSV vaccine for at-risk adults in their 50sThe RSV vaccine by GSK was previously approved only for adults 60 and older.
Source: CBSNews - 🏆 87. / 68 Read more »

Guillain-Barre syndrome 'more common than expected' with RSV vaccine in older people, CDC reiteratesReports of a rare nervous system disorder are “more common than expected” in older U.S. adults who got the new RSV vaccines.
Source: wjxt4 - 🏆 246. / 63 Read more »

Guillain-Barre syndrome 'more common than expected' with RSV vaccine in older people, CDC reiteratesReports of a rare nervous system disorder are “more common than expected” in older U.S. adults who got the new RSV vaccines
Source: sdut - 🏆 5. / 95 Read more »

Guillain-Barre syndrome 'more common than expected' with RSV vaccine in older people, CDC reiteratesReports of a rare nervous system disorder are “more common than expected” in older U.S. adults who got the new RSV vaccines.
Source: ksatnews - 🏆 442. / 53 Read more »

Guillain-Barre syndrome 'more common than expected' with RSV vaccine in older people, CDC reiteratesReports of a rare nervous system disorder are “more common than expected” in older U.S. adults who got the new RSV vaccines.
Source: KPRC2 - 🏆 80. / 68 Read more »

CDC strengthens RSV vaccine recommendation only for the oldest adultsNew CDC data showed that up to 39 states are seeing an uptick in Covid infections and experts are urging people to take extra safety measures to keep themselves and others healthy. NBC News’ medical contributor, Dr. Kavita Patel, breaks down the new CDC data.
Source: NBCNewsHealth - 🏆 707. / 51 Read more »